Anson Funds Management’s Celularity CELU Stock Holding History

Anson Funds Management’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-71,796	Closed	-$7.9M	–	260
2020 Q4	$7.9M	Buy	+71,796	New	+$7.63M	1.59%	15

Other funds holding CELU

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Anson Funds Management's CELU Position: Q1 2021 in Review

Anson Funds Management sold out of Celularity (CELU) in Q1 2021, closing a stake of 71,796 shares — an estimated $7.9M sold.

Anson Funds Management first reported a position in CELU in Q4 2020 and held it in 1 quarter. The position peaked at $7.9M in Q4 2020. 63 funds tracked by Wall St. Rank hold CELU as of Q1 2021.

Anson Funds Management reported no remaining Celularity position as of Q1 2021 after selling out during the quarter.
Anson Funds Management sold 71,796 Celularity shares in Q1 2021, an estimated $7.9M.
Anson Funds Management first reported a position in Celularity in Q4 2020 and held it in 1 quarter.
Anson Funds Management's Celularity position peaked at $7.9M in Q4 2020.
63 funds tracked by Wall St. Rank held Celularity as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.